Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

4402 - The level of circulating NKp46+ CD56dim CD16+ natural killer cells predicts distinct survival in non-small-cell-lung-cancer

Date

20 Oct 2018

Session

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

Presenters

Emilie Picard

Citation

Annals of Oncology (2018) 29 (suppl_8): viii483-viii487. 10.1093/annonc/mdy290

Authors

E. Picard1, Y. Godet1, C. Laheurte2, L. Boullerot1, E. Lauret Marie Joseph1, M. Jacquin3, V. Kaulek4, G. Eberst4, B. Gaugler1, P. Jacoulet4, M. Gainet-Brun4, J. Lahoucarde4, H. Almotlak4, F. Le Pimpec-Barthes5, E. Fabre-Guillevin6, C. Borg1, V. Westeel4, O. Adotevi1

Author affiliations

  • 1 /, Univ. Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, LabEx LipSTIC,, 25020 - Besançon/FR
  • 2 /, INSERM CIC-1431 Clinical Investigation Center in Biotherapies, Plateforme de Biomonitoring, 25020 - Besançon/FR
  • 3 /, CIC-1431, University Hospital of Besançon, 25000 - Besançon/FR
  • 4 /, University Hospital of Besançon, Department of Pneumology, 25000 - Besançon/FR
  • 5 /, Service de Chirurgie Thoracique, AP-HP, Hôpital Européen Georges Pompidou, 75000 - Paris/FR
  • 6 /, Service d’Oncologie Médicale, AP-HP, Hôpital Européen Georges Pompidou, 25000 - Paris/FR

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 4402

Background

Natural killer (NK) cells are innate effector lymphocytes involved in cancer immunosurveillance. Here we investigated the distribution, function and prognosis role of circulating NK cell subsets in non-small cell lung cancer (NSCLC).

Methods

Blood samples from 176 NSCLC patients were collected before any treatment and from 41 healthy donors (HD) as control. The phenotype and cytotoxic functions of NK cells were performed by multicolor flow cytometry. Kaplan–Meier method was used to estimate survival.

Results

NSCLC patients exhibited three distinct NK cell subsets in blood such as CD56dim CD16+, CD56dim CD16- and CD56bright NK cells. However, a lower rate of CD56dim CD16+ NK cells and a higher rate of CD56dim CD16- NK cells were found in patients as compared to HD. Unsupervised clustering analysis of activating receptors expression such as NKG2D, NKp30, NKp44, and NKp46 identified four groups of patients with distinct circulating NK cell profiles. We showed that the rate of circulating NKp46+ NK cells was inversely correlated with overall survival (OS). Consistently, the median OS in high versus low level NKp46+ NK cell group was 16 and 27 months respectively (P = 0.04). This effect was mainly driven by NKp46+ CD56dim CD16+ NK cells subset (P = 0.02). Finally, blocking NKp46 receptor in vitro was able to restore antitumor T cell immunity suggesting an inhibitory role of NKp46+ NK cells.

Conclusions

Altogether, our results show a distinct pattern of circulating NK cell subsets in NSCLC and also support the immune regulatory property of NKp46+ NK cell subsets. This study provides important insights on circulating Nkp46+ NK cell subsets as potential prognosis factor in lung cancer.

Clinical trial identification

Legal entity responsible for the study

Olivier Adotévi.

Funding

Assistance Publique des Hôpitaux de Paris, La Ligue Contre le Cancer, and the Conseil Régional de Franche-Comté.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.